Table 1.
Baseline characteristics of the study population used to evaluate LRG concentrations in the sera of patients with IBD and healthy individuals.
| Ulcerative colitis | Crohn's disease | Healthy individuals | |
|---|---|---|---|
| No. of participants | 98 | 96 | 92 |
| Sex (male/female) | 54/44 | 54/42 | 52/40 |
| Age (years) (median, IQR) | 41.6 (33.0–59.7) | 33.5 (24.3–48.9) | 39.6 (30.4–49.6) |
| Disease distribution | Proctitis/left-sided colitis/pancolitis 15/37/46 | Ileitis/colitis/ileocolitis 20/29/47 | — |
| Disease duration (years) (median, IQR) | 4.37 (1.0–9.0) | 9.1 (2.91–15.8) | — |
| Treatments | |||
| 5-Aminosalicylic acid (%) | Oral 72 (73.4), topical 26 (27.0) | Oral 76 (79.2) | — |
| Prednisolone (%) | Oral 17 (17.3), topical 8 (8.1) | Oral 14 (14.6) | — |
| Immunomodulator (%) | 22 (22.4) | 35 (37.1) | — |
| Leukocytapheresis (%) | 6 (6.1) | 1 (1.0) | — |
| Antitumor necrosis factor-α (%) | 7 (7.1) | 59 (61.5) | — |
| Indigo naturalis (%) | 19 (19.3) | 0 (0) | — |
| None (%) | 9 (9.1) | 9 (9.3) | — |
LRG: leucine-rich alpha-2 glycoprotein; IBD: inflammatory bowel disease; IQR: interquartile range.